Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Tomkins

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
Blood Advances|January 7, 2026
POD24 is a Novel Determinant of Prognosis in Patients with Waldenström MacroglobulinemiaSaurabh Zanwar, Jithma P Abeykoon, Shirley D'Sa, et al.
British Journal of Haematology|November 11, 2021
Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapyStephen Booth, Helen M Curley, Csilla Varnai, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
Blood Advances|January 7, 2026
POD24 is a Novel Determinant of Prognosis in Patients with Waldenström MacroglobulinemiaSaurabh Zanwar, Jithma P Abeykoon, Shirley D'Sa, et al.
British Journal of Haematology|November 11, 2021
Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapyStephen Booth, Helen M Curley, Csilla Varnai, et al.
Pageof 2